Premium
Monoclonal antibodies against vascular endothelial growth factor 165 (VEGF165): Neutralization of biological activity and recognition of the epitope
Author(s) -
Chen JunHui,
Wang XinChang,
Sato J. Denry
Publication year - 1999
Publication title -
iubmb life
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 113
eISSN - 1521-6551
pISSN - 1521-6543
DOI - 10.1080/15216549900201163
Subject(s) - antibody , monoclonal antibody , umbilical vein , vascular endothelial growth factor , epitope , neutralization , receptor , chemistry , microbiology and biotechnology , biology , vegf receptors , cancer research , immunology , biochemistry , in vitro
Five antibodies against vascular endothelial growth factor 165 (VEGF165) were obtained. These antibodies, Ab‐2, Ab‐20, Ab‐153, Ab‐309, Ab‐342, were able to recognize not only native VEGF165, but also reducing VEGF165. Three of the antibodies, Ab‐153, Ab‐309, Ab‐342, were identified as VEGF165 neutralizing antibody on the basis of its ability to inhibit the proliferation of human umbilical vein endothelial cells (HUVEC) induced by VEGF165 and the binding of [125I]‐VEGF165 to receptors on HUVEC. The fragments of E1 (VEGF120‐135) and E2 (VEGF46‐60) recognized by neutralizing antibodies may be related the receptor binding domain of VEGF.